Merck reported Q4 2025 revenue of $16.4 billion, up 5% (4% ex-FX), driven by Keytruda growth of 5% to $8.4 billion and a 6% increase in Animal Health, partially offset by a 35% decline in Gardasil sales due to weakness in China. Non-GAAP EPS for the quarter was $2.04. For full-year 2026, the company issued guidance for revenue of $65.5 to $67.0 billion (1% to 3% growth) and EPS of $5.00 to $5.15; however, excluding a ~$9.1 billion charge related to the Sidera acquisition, adjusted EPS is expected to be approximately $9.03. Management significantly increased its long-term commercial opportunity outlook to over $70 billion by the mid-2030s, up $20 billion from the previous year, citing strong progress in the pipeline including 18 positive Phase III trials in 2025. Strategic highlights include the successful launch of Ohtuvay for COPD, the acquisition of Sidera Therapeutics for the flu prevention candidate MK1406, and robust clinical progress in oncology (sacituzumab tirumotecan), cardiometabolic (enlicitide), and HIV (islatravir).
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Revenue | $16.4 billion | +5% |
| Q4 2025 Keytruda Sales | $8.4 billion | +5% |
| Q4 2025 Gardasil Sales | $1.0 billion | -35% |
| Q4 2025 EPS (Non-GAAP) | $2.04 | N/A |
| 2026 Revenue Guidance | $65.5 - $67.0 billion | +1% to +3% |
| 2026 EPS Guidance (Reported) | $5.00 - $5.15 | N/A |
| 2026 EPS Guidance (Ex-Sidera) | ~$9.03 | N/A |
| Pipeline Opportunity (Mid-2030s) | >$70 billion | +$20B YoY |
Management significantly de-risked the post-Keytruda narrative by increasing the commercial opportunity outlook to over $70 billion by the mid-2030s, a $20 billion increase from the prior year. This figure is more than double the consensus peak sales estimate for Keytruda ($35 billion). The signal here is that Merck's internal pipeline progress—specifically the 18 positive Phase III trials in 2025 and the initiation of 21 new Phase III trials—is outpacing external expectations. The company emphasized that 10 programs could be substantially clinically derisked over the next two years, covering the majority of this opportunity.
Merck is aggressively defending its Keytruda franchise, not just through clinical expansion but via intellectual property litigation. CEO Robert Davis expressed increased confidence in extending Keytruda's exclusivity beyond the 2028 compound patent expiry, citing two additional patents expiring in May and November 2029. While guidance remains conservative assuming 2028 LOE, this signal suggests a potential runway extension and a more gradual revenue cliff than currently modeled by consensus.
The acquisition strategy is shifting toward high-value assets that fill specific strategic gaps, evidenced by the purchases of Verona Pharma (Ohtuvay for COPD) and Sidera Therapeutics (MK1406 for flu). Management highlighted MK1406 as a 'greater than $5 billion revenue potential' asset, positioning it as a key driver for the next decade. This signals a disciplined but aggressive capital deployment strategy focused on infectious disease and respiratory expansion to diversify away from pure oncology reliance.
Merck is positioning itself as a leader in the TROP2 ADC space with sacituzumab tirumotecan (sac-TMT), differentiating through a broad development program of 16 Phase 3 studies. Unlike competitors who may narrow their focus to biomarker-selected populations, Merck is pursuing a 'workhorse' strategy across multiple tumor types, including first-in-class opportunities. This signals an intent to capture significant market share in the competitive ADC landscape by leveraging best-in-class potential and broad applicability.
The company is making a bold move in cardiometabolic disease with enlicitide, an oral PCSK9 inhibitor. By targeting the leading cause of death globally (CV disease) with an oral alternative to injectables, Merck is aiming to address a massive market. The publication of Phase III data in the New England Journal of Medicine and JAMA signals high scientific validation and a potential practice-changing shift in lipid management, supporting the $70B growth thesis.
The 2026 financial guidance presents a stark headline risk, with revenue growth projected at only 1% to 3% and reported EPS dropping significantly to $5.00-$5.15. While management attributes this to a one-time $9 billion charge for the Sidera acquisition, the adjusted EPS of ~$9.03 implies flat to modest growth compared to 2025. This raises concerns about the company's ability to generate top-line growth in the immediate term before the new pipeline ramps up, potentially leading to multiple compression.
Gardasil sales plummeted 35% in the quarter, driven by lower demand in China and Japan. While other international markets grew, the magnitude of the decline in China—a key growth engine—is alarming. Management noted 'lower demand' without providing a clear timeline for recovery, suggesting structural market saturation or competitive pressures that could persist and weigh on the Vaccines segment performance.
The launch of Inflonsia (RSV) is struggling, with only $21 million in sales. Management cited 'lower-than-expected infant immunization rates' and high channel inventory. This indicates significant execution challenges in a market that was expected to be a major growth driver. If these inventory issues and uptake hesitancy persist, it could cap the upside potential of the respiratory franchise in the near term.
Management acknowledged continued 'soft demand' for Lagevrio (COVID-19 antiviral). While this is a smaller product now, the persistent softness highlights the risk of relying on pandemic-era products that have rapidly diminishing relevance. It also adds to the list of products (along with Januvia/Bridion facing generics) creating a $2.5 billion headwind in 2026.
Despite the confident tone on the TROP2 ADC strategy, an analyst pressed Merck on why their development plan appeared 'conservative' compared to competitors like AstraZeneca and Daiichi. While management defended the strategy, the scrutiny suggests investors may perceive Merck as playing catch-up or taking a less aggressive stance in defining the standard of care in first-line settings, potentially limiting peak market share.
Overall: Management exhibited a highly confident and assertive tone throughout the call, particularly regarding the company's pipeline transformation and ability to weather the upcoming Keytruda LOE. CEO Robert Davis was notably defensive when questioned about the company's growth trajectory, firmly rejecting the characterization of Merck as a modest-growth company and emphasizing the strength of the underlying business ex-LOEs. Dr. Dean Li displayed scientific enthusiasm and precision when discussing clinical data, reinforcing the credibility of the pipeline strategy.
Confidence: HIGH - Management repeatedly used phrases like 'high confidence,' 'strong confidence,' and 'momentum is building.' They provided specific, quantified targets ($70B opportunity) and detailed patent defense strategies, indicating a high degree of certainty in their long-term plan despite near-term guidance headwinds.
$65.5 billion to $67.0 billion (1% to 3% growth)
$5.00 to $5.15 (Reported); ~$9.03 (Ex-Sidera charge)
Approximately 82%
$35.9 billion to $36.9 billion (Includes ~$9B Sidera charge)
23.5% to 24.5%
Hedging & Uncertainty: Management generally used strong, definitive language regarding the pipeline ('line of sight to over $70 billion', 'reshaping the standard of care'), but employed hedging when discussing immediate financial impacts and specific legal outcomes. For example, CFO Caroline Litchfield used the phrase 'potential that you are going to see protection actually make it through either May or November 2029' regarding Keytruda patents, avoiding a guarantee. Similarly, regarding the 2026 guidance impact, she used 'assumes' and 'approximately' to buffer against variability. However, the overall linguistic pattern shifted from hedging to assertiveness when challenged by analysts on growth prospects, with Rob Davis explicitly rejecting the premise of 'modest growth' questions.
The transformation of our portfolio is well underway, and momentum is building. - Robert M. Davis, Chairman and Chief Executive Officer
We have line of sight to over $70 billion of potential commercial opportunity by the mid-2030s. - Robert M. Davis, Chairman and Chief Executive Officer
WinRevir is reshaping the standard of care in PAH. - Dr. Dean Y. Li, President of Research Labs
Our confidence that we will be able to defend those additional two patents has grown. - Robert M. Davis, Chairman and Chief Executive Officer
I would challenge a little bit the characterization that we do not have a robust and ambitious program. - Dr. Dean Y. Li, President of Research Labs
We are entering a particularly robust period of first-time phase three data readouts. - Robert M. Davis, Chairman and Chief Executive Officer
This is the first pathway that is based on the genetics of vascular stability in the eye. - Dr. Dean Y. Li, President of Research Labs
Analyst Sentiment: Analysts expressed skepticism regarding the modest top-line growth guidance for 2026 and the competitive positioning of the TROP2 ADC program. Questions were probing, specifically asking for clarification on the 'conservative' nature of the pipeline strategy versus competitors and the sustainability of growth rates given recent headwinds.
Management Responses: Management responses were direct and at times confrontational, particularly CEO Rob Davis who firmly rejected the characterization of Merck as a low-growth company. Dr. Dean Li provided detailed, scientific rebuttals to questions about clinical strategy, emphasizing the breadth and differentiation of Merck's trials. The team effectively used the Q&A to highlight the 'hidden' strength of the business ex-one-time charges.
Discussion on the strategic positioning of sac-TMT (TROP2 ADC) versus competitors, with management emphasizing 16 Phase 3 studies and a 'workhorse' strategy.
Detailed debate on Keytruda patent life, with management confirming confidence in defending IP through 2029 while maintaining conservative guidance based on 2028.
Inquiry into the HIV dual regimen strategy, where management highlighted the unique mechanism of islatravir and the lack of integrase inhibitors.
Questions regarding the soft launch of Inflonsia (RSV) and the inventory dynamics in the market.
Analysis of the Winrevair launch trends, with management providing data on prescription growth and compliance.
Merck is successfully executing a complex portfolio transformation ahead of the 2028 Keytruda LOE. The Q4 earnings and 2026 guidance mask the underlying strength of the business, which is poised for significant growth driven by a deepening pipeline now valued at over $70 billion. The acquisition of Sidera (MK1406) and Verona (Ohtuvay), combined with internal progress in oncology (sac-TMT), cardiometabolic (enlicitide), and immunology (tulisokibart), provides a multi-pronged growth engine. While the 2026 reported EPS appears weak due to the Sidera charge, the adjusted EPS of ~$9.03 demonstrates robust core earnings power. Management's increased confidence in extending Keytruda exclusivity to 2029 provides further upside to current models. We view the current valuation as an attractive entry point ahead of a 'robust period of data readouts' in 2026-2027 that will de-risk the mid-2030s growth story.
Management noted a significant decline in Gardasil sales (-35%) driven by lower demand in China, signaling potential macroeconomic or competitive softness in this key pharmaceutical market.
The severity of the current flu season in the Northern Hemisphere was highlighted as a factor increasing the relevance of the ongoing ANCHOR trial for MK1406, potentially driving greater urgency for preventative flu therapies.
Management cited the IRA (Inflation Reduction Act) price setting as a $2.5 billion headwind for 2026, alongside generic competition, reflecting the ongoing pricing pressure in the US market.